Antineoplaston AS2-1 for maintenance therapy in liver cancer

  • Authors:
    • H Tsuda
    • M Sata
    • H Saitsu
    • K Yamana
    • H Hara
    • S Yamada
    • T Kumabe
  • View Affiliations

  • Published online on: November 1, 1997     https://doi.org/10.3892/or.4.6.1213
  • Pages: 1213-1216
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Antineoplaston AS2-1 exhibits cytostatic growth inhibition of human hepatocellular carcinoma cells in vitro and showed minimum adverse effects in a phase I clinical trial. Liver cancer is difficult to control because of multicentricity and underlying liver disease. We reviewed two clinical cases of liver cancer (hepatocellular carcinoma and multiple liver metastases from colon cancer) in whom we believe antineoplaston A2-1 was useful as a maintenance therapy after transcatheter arterial embolization (TAE) and microwave coagulation necrosis (MCN). The two patients have continued to be in good condition for more than two years without limitation of their normal activities. Antineoplaston AS2-1 may be effective and useful as a maintenance agent after TAE and MCN in patients with liver cancer.

Related Articles

Journal Cover

November 1997
Volume 4 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tsuda, H., Sata, M., Saitsu, H., Yamana, K., Hara, H., Yamada, S., & Kumabe, T. (1997). Antineoplaston AS2-1 for maintenance therapy in liver cancer. Oncology Reports, 4, 1213-1216. https://doi.org/10.3892/or.4.6.1213
MLA
Tsuda, H., Sata, M., Saitsu, H., Yamana, K., Hara, H., Yamada, S., Kumabe, T."Antineoplaston AS2-1 for maintenance therapy in liver cancer". Oncology Reports 4.6 (1997): 1213-1216.
Chicago
Tsuda, H., Sata, M., Saitsu, H., Yamana, K., Hara, H., Yamada, S., Kumabe, T."Antineoplaston AS2-1 for maintenance therapy in liver cancer". Oncology Reports 4, no. 6 (1997): 1213-1216. https://doi.org/10.3892/or.4.6.1213